Stephen Heitner
Experienced in Familial Progressive Cardiac Conduction Defect

Dr. Stephen Heitner

Cardiology
Heart RHYTHM Consultants P.C.
9427 SW Barnes Rd Ste 495, 
Portland, OR 
21 Years of Experience
Experienced in Familial Progressive Cardiac Conduction Defect
Heart RHYTHM Consultants P.C.
9427 SW Barnes Rd Ste 495, 
Portland, OR 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Stephen Heitner is a Cardiologist in Portland, Oregon. Dr. Heitner has been practicing medicine for over 21 years and is rated as an Experienced provider by MediFind in the treatment of Familial Progressive Cardiac Conduction Defect. His top areas of expertise are Hypertrophic Cardiomyopathy (HCM), Cardiomyopathy, Transthyretin Amyloidosis, Pacemaker Implantation, and Heart Bypass Surgery.

His clinical research consists of co-authoring 102 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Cardiology
Licenses
Internal Medicine in OR
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Heart RHYTHM Consultants P.C.
9427 SW Barnes Rd Ste 495, Portland, OR 97225

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Randomized, Double-Blind, Placebo-controlled, Single-ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of JK07 in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF)
A Randomized, Double-Blind, Placebo-controlled, Single-ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of JK07 in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF)
Enrollment Status: Completed
Publish Date: July 09, 2025
Intervention Type: Drug
Study Drug: JK07
Study Phase: Phase 1
An Open-Label Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in Study MYK-461-004 (PIONEER)
An Open-Label Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in Study MYK-461-004 (PIONEER)
Enrollment Status: Completed
Publish Date: January 09, 2025
Intervention Type: Drug
Study Drug: Mavacamten
Study Phase: Phase 2
Exercise in Genetic Cardiovascular Conditions (Lifestyle and Exercise in Hypertrophic Cardiomyopathy LIVE-HCM/Lifestyle and Exercise in the Long QT Syndrome LIVE-LQTS
Exercise in Genetic Cardiovascular Conditions (Lifestyle and Exercise in Hypertrophic Cardiomyopathy LIVE-HCM/Lifestyle and Exercise in the Long QT Syndrome LIVE-LQTS
Enrollment Status: Completed
Publish Date: September 05, 2023
A Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study to Assess the Safety and Tolerability of JK07 in Subjects With Heart Failure With Preserved Ejection Fraction (HFpEF)
A Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study to Assess the Safety and Tolerability of JK07 in Subjects With Heart Failure With Preserved Ejection Fraction (HFpEF)
Enrollment Status: Withdrawn
Publish Date: May 31, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Randomized, Double-blind, Placebo-controlled, Concentration-guided, Exploratory Study of Mavacameten in Patients With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM) and Preserved Left Ventricular Ejection Fraction
A Randomized, Double-blind, Placebo-controlled, Concentration-guided, Exploratory Study of Mavacameten in Patients With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM) and Preserved Left Ventricular Ejection Fraction
Enrollment Status: Completed
Publish Date: August 09, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double Blind, Placebo Controlled Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
A Randomized, Double Blind, Placebo Controlled Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Enrollment Status: Completed
Publish Date: October 04, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2 Open-label Pilot Study to Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
A Phase 2 Open-label Pilot Study to Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
Enrollment Status: Completed
Publish Date: June 08, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1, Open-label, Dose Escalation Study of Intravenous PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis
A Phase 1, Open-label, Dose Escalation Study of Intravenous PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis
Enrollment Status: Terminated
Publish Date: August 20, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis Who Have Persistent Cardiac Dysfunction
A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis Who Have Persistent Cardiac Dysfunction
Enrollment Status: Completed
Publish Date: April 05, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2b Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of NEOD001 in Subjects With Light Chain (AL) Amyloidosis Who Were Previously Enrolled in Study NEOD001-201 (PRONTO)
A Phase 2b Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of NEOD001 in Subjects With Light Chain (AL) Amyloidosis Who Were Previously Enrolled in Study NEOD001-201 (PRONTO)
Enrollment Status: Terminated
Publish Date: March 26, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

102 Total Publications

Efficacy and Safety of Aficamten in Children and Adolescents With Obstructive Hypertrophic Cardiomyopathy: Study Design and Rationale of CEDAR-HCM.
Efficacy and Safety of Aficamten in Children and Adolescents With Obstructive Hypertrophic Cardiomyopathy: Study Design and Rationale of CEDAR-HCM.
Journal: Circulation. Heart failure
Published: December 05, 2025
Similar Doctors
Distinguished in Familial Progressive Cardiac Conduction Defect
Dr. Michael A. Wilson
Cardiology | Interventional Cardiology
Distinguished in Familial Progressive Cardiac Conduction Defect
Dr. Michael A. Wilson
Cardiology | Interventional Cardiology
9427 Southwest Barnes Road, Suite 495, 
Portland, OR 
 (4.0 miles away)
503-962-1000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Wilson is a Cardiologist and an Interventional Cardiologist in Portland, Oregon. Dr. Wilson is rated as an Advanced provider by MediFind in the treatment of Familial Progressive Cardiac Conduction Defect. His top areas of expertise are Familial Progressive Cardiac Conduction Defect, Arrhythmias, Heart Attack, Angina, and Pacemaker Implantation. Dr. Wilson is currently accepting new patients.

Distinguished in Familial Progressive Cardiac Conduction Defect
Dr. Ashit G. Patel
Cardiac Electrophysiology | Cardiology
Distinguished in Familial Progressive Cardiac Conduction Defect
Dr. Ashit G. Patel
Cardiac Electrophysiology | Cardiology

Cascade Cardiology LLC

777 Commercial St Se, Suite 130, 
Salem, OR 
 (42.8 miles away)
503-485-4787
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Ashit Patel is a Cardiac Electrophysiologist and a Cardiologist in Salem, Oregon. Dr. Patel is rated as a Distinguished provider by MediFind in the treatment of Familial Progressive Cardiac Conduction Defect. His top areas of expertise are Sick Sinus Syndrome, Arrhythmias, Familial Progressive Cardiac Conduction Defect, Pacemaker Implantation, and Cardiac Ablation. Dr. Patel is currently accepting new patients.

Distinguished in Familial Progressive Cardiac Conduction Defect
Dr. Alexi P. Zemsky
Cardiac Electrophysiology | Cardiology
Distinguished in Familial Progressive Cardiac Conduction Defect
Dr. Alexi P. Zemsky
Cardiac Electrophysiology | Cardiology
4400 Northeast Halsey Street, Building 1, 
Portland, OR 
 (5.0 miles away)
503-962-1000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Alexi Zemsky is a Cardiac Electrophysiologist and a Cardiologist in Portland, Oregon. Dr. Zemsky is rated as a Distinguished provider by MediFind in the treatment of Familial Progressive Cardiac Conduction Defect. His top areas of expertise are Arrhythmias, Atrial Fibrillation, Atrioventricular Nodal Reentrant Tachycardia (AVNRT), Pacemaker Implantation, and Cardiac Ablation. Dr. Zemsky is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Heitner's expertise for a condition
ConditionClose
View All 32 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile